$APGE

Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false Apogee Therapeutics, Inc. 0001974640 CA NASDAQ 0001974640 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Ear

Apogee Therapeutics, Inc. (APGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apge-ex99_1.htm EX-99.1 EX-99.1 Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immuno

Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $134.17 ($0.74M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Baron Health Care Fund’s Q2 2026 investor letter reported the fund gained 11.99% in the quarter. It said it sold Apogee Therapeutics (NASDAQ:APGE) after Apogee agreed to be acquired by AbbVie (AbbVie Inc.) for $135.11 per share, a 49.5% premium. APGE closed at $134.19 on Aug. 4, 2026.

AbbVie (ABBV) said June 22 it will acquire Apogee Therapeutics (APGE) for $10.9 billion in cash. The deal would add zumilokibart for eczema to AbbVie’s immunology portfolio. The article discusses potential effects on AbbVie’s dividend, citing AbbVie’s 2025 free cash flow estimate of $17.8 billion and its dividend growth record.

PwC estimates over $300 billion in branded pharma revenue will lose patent exclusivity by decade end, driving large drugmakers to buy pipelines. ALPS Advisors says biopharma deal value could exceed $250B in 2026. The ALPS Medical Breakthroughs ETF (SBIO) added 37 names in June; it holds ABBV’s $10.9B Apogee deal target APGE and Definium (DFTX).

Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson filed an SEC Form 4 showing he disposed of 95,046 shares on July 8 and July 10, 2026. Of this, 75,046 shares were gifted to a donor-advised fund and 20,000 were sold under a Rule 10b5-1 plan. Henderson retained about 920,941 shares. APGE reported a TTM net loss of $274.6 million and its stock rose about 247% over the prior year.

HENDERSON MICHAEL THOMAS (Chief Executive Officer) sold 20,000 shares of Apogee Therapeutics, Inc. (APGE) at $133.63 ($2.67M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $132.74 ($0.73M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).